Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,255.60
(
0.51%
)
Dow Jones
46,993.26
(
0.00%
)
Brent Oil
101.73
(
1.07%
)
Bitcoin
72,912.64
(
-1.39%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 115460

Thursday, 02/24/2011 4:47:28 PM

Thursday, February 24, 2011 4:47:28 PM

Post# of 257253
Nice profile piece on Biocon’s founder. Generic insulin could work out well for PFE; the FDA regulates insulin as a small-molecule drug rather than a biologic, and hence generic versions of the insulins from NVO, LLY, and SNY would be automatically substitutable for their branded counterparts.

When PFE announced the Biocon deal in Oct 2010 (#msg-55680051), NVO’s quickly stock fell 10% (#msg-55717310).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now